For these rare types of mutations, the results of the AURA3 clinical trial indicated that osimertinib showed greater efficacy and lower toxicity than platinum–pemetrexed therapy after a first‐line EGFR‐TKI therapy for NSCLC with the EGFR T790M mutation.7 Here, EGFR is linked to non-small cell lung carcinoma.